Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
China
Peking University First Hospital, Beijing, Beijing Municipality Beijing TianTan Hospital,Capital Medical University, Beijing, Beijing Municipality Beijing Cancer Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong Guangxi Medical University Cancer Hospital, Nanning, Guangxi The Third People's Hospital of Zhengzhou, Zhengzhou, Henan Hunan Cancer Hospital, Changsha, Hunan Hunan Cancer Hospital, Changsha, Hunan Nanjing Drum Tower Hospital, Nanjing, Jiangsu Nanjing Drum Tower Hospital, Nanjing, Jiangsu Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang